APA (7th ed.) Citation

Frenel, J., Kim, J., Berton-Rigaud, D., Asher, R., Vidal, L., Pautier, P., . . . Pujade-Lauraine, E. (2020). 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial. Annals of Oncology, 31, S615. https://doi.org/10.1016/j.annonc.2020.08.952

Chicago Style (17th ed.) Citation

Frenel, J-S, et al. "813MO Efficacy of Subsequent Chemotherapy for Patients with BRCA1/2 Mutated Platinum-sensitive Recurrent Epithelial Ovarian Cancer (EOC) Progressing on Olaparib Vs Placebo: The SOLO2/ENGOT Ov-21 Trial." Annals of Oncology 31 (2020): S615. https://doi.org/10.1016/j.annonc.2020.08.952.

MLA (9th ed.) Citation

Frenel, J-S, et al. "813MO Efficacy of Subsequent Chemotherapy for Patients with BRCA1/2 Mutated Platinum-sensitive Recurrent Epithelial Ovarian Cancer (EOC) Progressing on Olaparib Vs Placebo: The SOLO2/ENGOT Ov-21 Trial." Annals of Oncology, vol. 31, 2020, p. S615, https://doi.org/10.1016/j.annonc.2020.08.952.